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Abstract 26 
Insulin resistance is central to the development of type 2 diabetes and related metabolic 27 
disorders. As skeletal muscle is responsible for the majority of whole body insulin-stimulated 28 
glucose uptake, regulation of glucose metabolism in this tissue is of particular importance. 29 
While Rho GTPases and many of their affecters influence skeletal muscle metabolism, there 30 
is a paucity of information on the protein kinase N (PKN) family of serine/threonine protein 31 
kinases. We investigated the impact of PKN2 on insulin signaling and glucose metabolism in 32 
primary human skeletal muscle cells in vitro and mouse tibialis anterior muscle in vivo. 33 
PKN2 knockdown in vitro decreased insulin-stimulated glucose uptake, incorporation into 34 
glycogen and oxidation. PKN2 siRNA increased 5’ adenosine monophosphate-activated 35 
protein kinase (AMPK) signaling, while stimulating fatty acid oxidation and incorporation 36 
into triglycerides, and decreasing protein synthesis. At the transcriptional level, PKN2 37 
knockdown increased expression of PGC1α and SREBP1c and their target genes. In mature 38 
skeletal muscle, in vivo PKN2 knockdown decreased glucose uptake and increased AMPK 39 
phosphorylation. Thus, PKN2 alters key signaling pathways and transcriptional networks to 40 
regulate glucose and lipid metabolism. Identification of PKN2 as a novel regulator of insulin 41 
and AMPK signaling may provide an avenue for manipulation of skeletal muscle 42 
metabolism.  43 
 44 
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INTRODUCTION 48 
As skeletal muscle is the predominant site of insulin-stimulated glucose uptake, skeletal 49 
muscle insulin resistance is a major contributing factor to defective blood glucose disposal in 50 
type 2 diabetes (5, 6). The physiological role of novel and previously identified candidate 51 
genes/proteins that regulate inter- and intra-cellular signaling pathways controlling cellular 52 
and whole body glucose and lipid homeostasis is an active area of current research. Through 53 
the discovery of key regulatory proteins in glucose and energy homeostasis, new diabetes 54 
prevention and treatment targets may be identified.  55 
The Rho family of guanosine triphosphatases (GTPases), comprised of Rho, Rac and 56 
CDC42, are essential regulators of diverse biological functions including glucose 57 
metabolism. In particular, Rac1 is essential for both insulin-dependent and independent 58 
glucose uptake in skeletal muscle (31, 32). Rho GTPases utilize protein kinases to elicit many 59 
of their downstream effects. Among the Ser/Thr kinases that function as Rho GTPase effector 60 
molecules are Rho- (ROCK1/2), p21-activated (PAK1-PAK6), and protein kinase N (PKN1-61 
PKN3) kinases (38). While members of the ROCK and PAK family have well-established 62 
roles in glucose metabolism and insulin signaling, little is known regarding the function of 63 
PKNs in skeletal muscle metabolic regulation (12, 33, 34).   64 
PKNs are members of the atypical protein kinase C subfamily known for regulating actin 65 
cytoskeletal rearrangement and cell migration. While the three mammalian PKN family 66 
members share a large degree of homology in their C-terminal catalytic domain, variation in 67 
their regulatory domain results in selectivity to upstream signals (17, 21). Both PKN1 and 68 
PKN2 respond to Rho and Rac, but these isoforms display differential responsiveness to 69 
lipids and binding partner proteins (10, 11, 13, 21, 24, 26). Importantly, PKN2 represents the 70 
majority of Rho associated autophosphorylation activity in all tissues tested (36). A high 71 
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degree of isoform selectivity was confirmed by the finding that mice lacking PKN1, PKN3 or 72 
both are without overt phenotype, while loss of PKN2 is embryonically lethal (25).  73 
In addition to Rho GTPases, phosphoinositide-dependent kinase-1 (PDK1), a key kinase 74 
in the insulin signaling cascade, stimulates PKNs by phosphorylation of the activation loop 75 
(9). In adipocytes, insulin stimulates PKN activity and PKN1 transmits the insulin signal to 76 
the actin cytoskeleton (9, 30). Conversely, PKNs may inhibit insulin signaling by directly 77 
interacting with PDK1 and Akt (8, 15, 35). In C2C12 cells, PKN2 contributes to cell 78 
adhesion-mediated activation of Akt (18). Moreover, phosphoproteomics of PKN2
-/-
 mouse 79 
embryonic fibroblasts revealed elevations in the Akt pathway (25). As PKN2 is the 80 
predominant PKN isoform in skeletal muscle, we investigated a potential role for PKN2 in 81 
metabolic regulation in this tissue (7). We found that PKN2 knockdown impairs insulin 82 
responsive glucose metabolism and, unexpectedly, activates 5’ adenosine monophosphate-83 
activated protein kinase (AMPK) with downstream effects on lipid and protein metabolism.  84 
 85 
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MATERIALS AND METHODS 87 
Cell culture and transfection. 88 
Primary human skeletal muscle cell (HSMCs) cultures were established from vastus lateralis 89 
biopsies taken from healthy men as previously described (1). Cells were grown and 90 
differentiated as previously described (19). On days 4 and 6 of differentiation, myotubes were 91 
transfected with 25 nM small interfering RNA (siRNA) targeting PKN2 or scrambled control 92 
(781 and Negative Control No. 2, respectively, Ambion) utilizing Lipofectamine RNAiMax 93 
(Invitrogen) according to manufacturer’s instructions. All experiments were performed on 94 
day 8 of differentiation. Hek293 cells were grown in DMEM (#31966, Thermofisher) 95 
supplemented with 10% FBS. Cells were co-transfected with siRNA (25 nM) and plasmid (1 96 
μg/ml) utilizing Lipofectamine 2000 (Invitrogen) according to manufacturer’s instructions 48 97 
h prior to harvest. The plasmid encoding constitutively active Fyn kinase was a gift from Dr. 98 
Jeffrey Pessin (37). All experiments were performed in technical triplicate and results were 99 
normalized to protein content determined by the bicinchoninic acid assay (Pierce) with the 100 
exception of lipid fate. DNA content was quantified by the Qubit dsDNA HS assay 101 
(Thermofisher).  102 
 
103 
Glucose uptake, incorporation into glycogen and glucose oxidation in HSMCs 104 
2-deoxyglucose uptake was measured as previously described (19). Briefly, 4 h serum starved 105 
HSMCs were incubated with 120 nM insulin or vehicle control for one hour. Following a 106 
PBS wash, glucose free media with 
3
H 2-deoxyglucose and 10 µM 2-deoxyglucose was 107 
added to the cells for 15 minutes. Cells were lysed in 0.03% SDS and the lysate analysed for 108 
protein concentration and 
3
H
 
content.  Glucose incorporation into glycogen was determined 109 
as previously described (22). Transfected HSMCs were incubated in the absence or presence 110 
of 120 nM insulin for 2 hours with an addition of 
14
C-glucose for the final 90 minutes. 111 
Glycogen was precipitated from cell lysate and analyzed for 
14
C content. Glucose oxidation 112 
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was performed as previously described (2). Transfected HSMCs were incubated with 
14
C-113 
glucose in the absence or presence of 120 nM insulin. Plates were sealed for 4 h to 114 
accumulate radioactive 
14
CO2, which was captured and analyzed in 2 M NaOH following 115 
acidification of the media with 2 M HCl.  116 
 117 
Fatty Acid Oxidation and lipid fate. 118 
Fatty acid oxidation was measured as previously described (22). HSMCs were incubated in 119 
media with 
3
H-palmitate and 25 μM of unlabeled palmitate with or without 5-120 
aminoimidazole-4-carboxamide-1-β-4-ribofuranoside (AICAR) (2 mM). Following 6 hours 121 
incubation, palmitate was stripped from the media by incubation with charcoal and 
3
H 122 
content in the palmitate-free media assessed. Lipid fate was measured as previously described 123 
(20). Transfected HSMCs were incubated with 
14
C-palmitate in the absence or presence of 124 
AICAR (2 mM) for 6 hours. Total cellular lipids were extracted utilizing isopropanol-hexane-125 
KCl (2:4:1), dried, reconstituted in chloroform/methanol (1:1), spotted on thin-layer 126 
chromatography (TLC) plates (Whatman), and separated in a hexane-diethylether-acetic acid 127 
(80:20:3) system. Lipid species were quantified by autoradiography. 128 
 129 
Protein synthesis  130 
Transfected HSMCs were incubated with 
3
H-phenylalanine and 2 mM unlabeled 131 
phenylalanine for 6 hours. Following 4 washes with ice cold PBS, cells were lysed in 0.03% 132 
SDS. 
3
H content was determined in trichloroacetic acid precipitate of the cell lysate. 133 
 134 
Animals and in vivo experimental protocol. 135 
All animal procedures have been approved by the Regional Animal Ethical Committee of 136 
Northern Stockholm. Male C57BL/6J mice (12–14 weeks old) were purchased from Charles 137 
 7 
River (Sulzfeld, Germany) and acclimatized for at least 1 week before use. Mice were housed 138 
in a humidity- and temperature-controlled environment with 12 h light:12 h darkness cycle 139 
and provided ad libitum access to water and standard rodent chow (4% fat, 16.5% protein, 140 
58% carbohydrates, 3.0 kcal/g purchased from Lantmännen, Stockholm, Sweden). Tibialis 141 
anterior muscles of adult C57BL/6J mice were transfected with either Sure Silencing GFP 142 
negative control or a mixture of 4 plasmids encoding short hairpin RNAs (shRNAs) targeting 143 
PKN2 (KM34588G, Qiagen) by electroporation as described previously (16). One week after 144 
electroporation, mice were fasted for 4 h and subjected to a modified oral glucose tolerance 145 
test to assess glucose uptake into skeletal muscle, as described (16). Glycogen content was 146 
determined as previously described (19). For insulin signaling experiments, male C57BL/6J 147 
mice (12 weeks old) were fasted for 4 h and treated I.P. with insulin (5 units/kg) or saline for 148 
15 min. Mice were anesthetized with Avertin and electroporated or quadriceps muscle 149 
removed and frozen immediately. 150 
 151 
Western Blot analysis. 152 
Transfected cells were harvested, placed on Laemmli buffer and subjected to Western Blot 153 
analysis as previously described (19). Ponceau staining was used to confirm equal protein 154 
loading. Membranes were also probed against β-actin to control for equal loading of proteins. 155 
Proteins were quantified by densitometry utilizing Quantity One Software (Bio-Rad). The 156 
quantifications displaying statistical significance or trends (p<0.1) are presented in the 157 
manuscript in graphical format. Antibodies used are given in Table 1.  158 
 159 
RNA extraction and mRNA expression quantification.  160 
mRNA was extracted from HSMC and skeletal muscle tissue with the RNeasy Mini Kit 161 
(Qiagen,) and TRIzol reagent (Invitrogen,) respectively, according to the manufacturer's 162 
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recommendations. cDNA synthesis and semi-quantitative real-time PCR was performed as 163 
previously described (19). Primer sequences are presented in Table 2. 164 
 165 
Statistical analysis. 166 
Statistical analyses were performed using GraphPad Prism 7.0 (GraphPad Software. San 167 
Diego, CA). Two-way analysis of variance was performed on untransformed data to assess 168 
the effects of siRNA and compounds. Data is presented as fold change to remove inter-cell 169 
line variation for visualization purposes. Paired t-test analysis was utilized for single variable 170 
experiments. Significance was set at p<0.05. Data is presented as mean ± SEM. 171 
 172 
173 
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RESULTS 174 
Gene silencing of PKN2 does not alter myotube differentiation.  175 
To assess the impact of PKN2 on skeletal muscle metabolism, primary human skeletal 176 
muscle cells were transfected with PKN2 siRNA on days 4 and 6 after the initiation of 177 
differentiation. This treatment achieved a robust knockdown of PKN2 mRNA and protein 178 
(Fig 1A and 1B). As PKN2 regulates myotube differentiation in C2C12 cells (18), we sought 179 
to ensure that PKN2 knockdown did not alter the differentiation status of the human 180 
myotubes used here. Visual appearance of cultures, as well as mRNA expression and protein 181 
abundance of myogenic (desmin) and proliferative markers (PAX7) were unchanged (Fig 1A, 182 
1B and 1C). Myotube protein to DNA ratio was unchanged by siRNA treatment (Scr: 183 
0.84±0.07 mg protein/mg DNA; PKN2: 0.86±0.05 mg protein/mg DNA; n=5). 184 
 185 
Role of PKN2 in glucose metabolism and insulin signaling.   186 
Having established that PKN2 knockdown does not alter the differentiation status of HSMCs, 187 
we utilized radioactive tracer based methods to assess glucose metabolism. PKN2 188 
knockdown decreased insulin-stimulated glucose uptake and incorporation into glycogen 189 
without altering basal glucose metabolism (Fig 1D and 1E). Similarly, insulin-stimulated 190 
glucose oxidation was diminished in cells depleted of PKN2 (Fig 1F).  191 
PKN2 has been reported to be phosphorylated by PDK1 (9). Given that PKN2 192 
knockdown diminished insulin-responsiveness of glucose metabolism, we sought to 193 
determine if PKN2 constitutes a branch of, or otherwise influences, insulin signaling. 194 
Western blot analysis revealed that insulin treatment of either HSMC (Fig 2A) or mouse 195 
quadriceps muscle (Fig 2B) did not alter phosphorylation of the activation loop in either 196 
PKN2 or PKN1. PKN2 knockdown did not alter the phosphorylation of Akt or GSK3α/β (Fig 197 
2A). However, PKN2 knockdown increased phosphorylation of TBC1D4 under both basal 198 
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and insulin-stimulated conditions in HSMC (Fig 2A, 2C). Thus, the activation loop of PKN2 199 
does not appear to be phosphorylated in response to insulin. Furthermore, decreased insulin-200 
stimulated glucose metabolism in PKN2 knockdown cells cannot be explained by altered 201 
phosphorylation within the canonical insulin signaling cascade.   202 
 203 
PKN2 gene silencing increases AMPK signaling.  204 
As PKN2 knockdown impaired insulin-responsiveness of glucose metabolism, we sought to 205 
examine whether PKN2 influences AMPK signaling. PKN2 knockdown increased the 206 
phosphorylation of AMPK and its substrate ACC (Fig 3A-C). Fyn kinase inhibits AMPK 207 
activity by sequestering LKB1 in the nucleus (37). As PKN2 activates Fyn kinase, we 208 
determined whether PKN2 knockdown increases AMPK signaling by decreasing Fyn kinase 209 
activity using constitutively active Fyn kinase (caFyn) in HEK293 cells (28, 37). Increased 210 
phosphorylation of ACC upon knockdown of PKN2 persisted, irrespective of caFyn 211 
overexpression (Fig 3D). Thus, PKN2 knockdown increases AMPK signaling independently 212 
of Fyn kinase.   213 
 214 
PKN2 gene silencing increases lipid metabolism and genes involved in lipid handling. 215 
To determine if PKN2 knockdown influences lipid metabolism, fatty acid oxidation and lipid 216 
fate was assessed in HSMC incubated in the absence or presence of the AMPK activator 217 
AICAR. PKN2 knockdown increased both basal and AICAR-stimulated fatty acid oxidation 218 
(Fig 4A). Similar to AICAR treatment, PKN2 knockdown decreased palmitate incorporation 219 
into 1,3-diacylglycerol and the origin, which contains polar lipids (Fig 4B). Interestingly, 220 
PKN2 markedly increased incorporation of palmitate into triglycerides (Fig 4B). To gain 221 
insight into mechanisms by which PKN2 alters lipid metabolism, we performed qPCR 222 
analysis of genes involved in lipid handling and synthesis. PKN2 knockdown increased 223 
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expression of the transcriptional co-activator PGC-1α and several of its target genes (CPT1β, 224 
PDK4, FABP3) (Fig 4C). PKN2 silencing also increased expression of genes involved in 225 
fatty acid synthesis (SCD1, FASN, SREBP1c) and, unexpectedly, decreased the expression 226 
of genes involved in triglyceride synthesis (DGAT1 and GPAT1) (Fig 4D). 227 
 228 
PKN2 gene silencing decreased mTOR signaling and protein synthesis.  229 
As PKN2 knockdown led to increased AMPK signaling, we determined whether downstream 230 
targets involved in protein metabolism might also be altered. Consistent with AMPK 231 
activation, PKN2 knockdown decreased both basal and insulin-stimulated phosphorylation of 232 
mTOR and S6 ribosomal protein (Fig 5A-C). To determine whether these changes were 233 
associated with alterations in protein metabolism, we performed a protein synthesis assay. 234 
PKN2 knockdown decreased incorporation of phenylalanine into protein (Fig 5D). Consistent 235 
with AMPK activation, PKN2 knockdown decreased mTOR signaling and protein synthesis. 236 
 237 
PKN2 knockdown in mature skeletal muscle.  238 
To assess the impact of PKN2 gene silencing in mature skeletal muscle in vivo, contralateral 239 
tibialis anterior muscles were electroporated with shRNA targeting PKN2 or a scrambled 240 
control sequence. PKN2 shRNA produced a modest decrease in both PKN2 mRNA 241 
expression (77±11% of control leg) and protein abundance (Fig 6A, 6B). To determine 242 
whether PKN2 gene silencing affects glucose uptake in adult skeletal muscle in vivo, we 243 
performed a modified oral glucose tolerance test utilizing radiolabeled 2-deoxyglucose. 244 
PKN2 depletion reduced glucose uptake in tibialis anterior muscle (Fig 6C). Similarly, PKN2 245 
silencing was associated with a trend (p=0.07) for decreased glycogen content in skeletal 246 
muscle (Fig 6D). We next determined whether PKN2 silencing activates AMPK signaling, by 247 
assessing phosphorylation of AMPK and its substrate ACC in adult skeletal muscle. Similar 248 
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to our in vitro results, PKN2 silencing was associated with an increase in the phosphorylation 249 
of AMPK (Fig 6A, 6E) and its substrate ACC, although ACC phosphorylation did not reach 250 
statistical significance (Fig 6A, 6F). Thus, PKN2 knockdown in vivo inhibits glucose uptake 251 
during a glucose challenge and activates AMPK signaling in mature skeletal muscle.  252 
 253 
254 
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DISCUSSION 255 
Insulin and AMPK are powerful regulators of metabolism in skeletal muscle. Insulin favors 256 
cell growth and energy storage, while AMPK signals energy stress within the cell to favor 257 
catabolic processes. Here, we provide evidence that PKN2 depletion in skeletal muscle 258 
impairs insulin-responsiveness of glucose metabolism and augments AMPK signaling with 259 
concomitant effects on protein and lipid metabolism. The late initiation and duration of PKN2 260 
knockdown utilized in the present study may explain the non-effects on myotube 261 
differentiation and hypotrophy, despite previous findings in C2C12 cells and observed 262 
decreases in protein synthesis, respectively (18).  263 
A complex network of insulin-regulated signals control glucose metabolism. These 264 
signals include Rho GTPases and their effector molecules. As PKN2 silencing reduced 265 
insulin-simulated glucose uptake in HSMCs and glucose uptake during a glucose challenge in 266 
adult skeletal muscle, it may function as an effector protein in the insulin signaling network. 267 
Given that PKN2 knockdown impairs insulin-stimulated glucose uptake despite stimulating 268 
two distinct signals, phosphorylation of TBC1D4 on Ser
318
 and activation of AMPK, that 269 
normally stimulate glucose uptake, PKN2 likely functions downstream of Rab GTPases to 270 
facilitate insulin-stimulated glucose metabolism.  PKN2 is known to regulate the cytoskeleton 271 
(36). Thus, PKN2 may play a role in relaying the insulin signal to the cytoskeleton in skeletal 272 
muscle by a mechanism analogous to that of PKN1 in adipocytes (9).  The exact nature of 273 
PKN2’s role in transducing the insulin signal to downstream targets remains unclear. 274 
Although we could not detect alterations in PKN2 phosphorylation in response to insulin, we 275 
cannot exclude the possibility that insulin treatment alters PKN2 activity or localization (30). 276 
Aside from a potential role within the insulin signaling cascade, PKN2 has been shown to 277 
influence Akt signaling both by directly binding to PDK1 and indirectly influencing its 278 
activity (8, 15, 35). Unbiased phosphoproteomic studies reveal Akt signaling is decreased in 279 
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PKN2
-/-
 mouse embryonic fibroblasts (25). While we did not detect changes in Akt or 280 
GSK3α/β phosphorylation, we found phosphorylation of Ser318 on TBC1D4 was increased 281 
upon PKN2 knockdown. Serine 318 on TBC1D4 is phosphorylated by Akt in response to 282 
insulin, but not by AMPK activation. Target and context specific activation of Akt signaling 283 
is supported by the finding that PKN2 functions in a complex with adaptor protein, 284 
phosphotyrosine interacting with PH domain and leucine zipper 1 (APPL1) and cell adhesion 285 
molecule-related downregulated by oncogene (CDO) to increase Akt phosphorylation in 286 
differentiating, but not proliferating, myoblasts (18). Interestingly, APPL1 inhibition 287 
phenocopies the effect of PKN2 silencing on glucose uptake, glycogen content and AMPK 288 
signaling (4). Thus, APPL1 and PKN2 may share common points of action in the regulation 289 
of glucose metabolism. Another member of the APPL family, APPL2, has been shown to 290 
interact with TBC1D1 and control its phosphorylation (3). The mechanism by which PKN2 291 
influences TBC1D4 phosphorylation requires further study.  292 
AMPK is a cellular energy sensor that influences lipid, glucose, and protein metabolism, 293 
as well as gene expression. PKN2 depletion in vitro and in vivo augments AMPK signaling, 294 
but the mechanism is unclear. PKN2 activates Fyn kinase to regulate cell adhesion in 295 
keratinocytes (28). Notably, Fyn kinase-induced phosphorylation of LKB1 regulates AMPK 296 
activity by sequestering LKB1 in the nucleus (37). Thus, inhibition of Fyn kinase may be 297 
responsible for AMPK activation upon PKN2 knockdown. However, our finding of a 298 
persistent AMPK activation by PKN2 knockdown in the presence of constitutively active Fyn 299 
kinase demonstrates that Fyn kinase is dispensable. Interestingly, several Rho kinase 300 
inhibitors known to activate AMPK and influence obesity-related insulin resistance also 301 
inhibit PKN2 (14, 23).  302 
AMPK signaling inhibits mTOR and ACC to decrease protein synthesis and increase lipid 303 
oxidation, respectively. Consistent with activation of AMPK, PKN2 knockdown decreased 304 
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protein synthesis and stimulated fatty acid oxidation. Our findings that PKN2 knockdown 305 
decreased phosphorylation of mTOR and S6 ribosomal protein are consistent with decreased 306 
S6 kinase phosphorylation in PKN2
-/-
 mouse embryonic fibroblasts (25). AMPK controls 307 
lipid metabolism by phosphorylating ACC, as well as by activating transcriptional regulators. 308 
PKN2 knockdown increased expression of PGC1α and several of its target genes (29). 309 
Despite decreased expression of genes involved in triglyceride synthesis, PKN2 knockdown 310 
increased palmitate incorporation into triglycerides. This altered partitioning of fatty acids 311 
towards oxidation and triglyceride synthesis and away from diacylglycerol also occurs upon 312 
AMPK activation and in response to exercise (27).  313 
Taken together our results demonstrate that PKN2 is a novel regulator of insulin-314 
stimulated glucose metabolism and AMPK signaling in skeletal muscle. Additionally, our 315 
findings suggest that PKN2 knockdown phenocopies APPL1 inhibition, supporting the notion 316 
that these two proteins may function together in a signaling complex (4). Further 317 
understanding of the role of PKN2 in controlling key signaling and metabolic events in 318 
skeletal muscle could aid in the treatment of insulin resistance in type 2 diabetes.  319 
 320 
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Table 1: Antibodies Used 456 
Target Catalogue # Company 
PKN2 (cells) 8697 Cell Signaling 
PAX7 27-583 Prosci, Inc 
DES 15200 Abcam 
β-ACTIN A5541 Sigma 
Phospho-PKN1/2 (Thr
774/816
) 2611 Cell Signaling 
Phospho-Akt (Ser
473
) 9271 Cell Signaling 
Phospho-Akt (Thr
308
) 4056 Cell Signaling 
Akt 9272 Cell Signaling 
Phospho-GSK-3α/β (Ser21/9) 9331 Cell Signaling 
GSK3 β 9315 Cell Signaling 
P-TBC1D4 8619 Cell Signaling 
TBC1D4 07-741 EMB Millipore 
Phospho-mTOR (Ser
2448
)  5536 Cell Signaling 
mTOR (7C10) 2983 Cell Signaling 
P-AMPK (Thr
172
) 2531 Cell Signaling 
AMPK 2532 Cell Signaling 
P-ACC (Ser
79
) 3661 Cell Signaling 
ACC 3676 Cell Signaling 
Fyn sc-16 Santa Cruz 
GAPDH 25778 Santa Cruz 
P-S6 (Ser
235/236
) 2211 Cell Signaling 
S6 2317 Cell Signaling 
PKN2 (mouse muscle) 2612 Cell Signaling 
 457 
458 
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 459 
Table 2: Primers Used 460 
Human Forward Reverse 
rplo TGGAGAAACTGCTGCCTCAT GATTTCAATGGTGCCCCTGG 
ppia AGGGTTCCTGCTTTCACAGA CAGGACCCGTATGCTTTAGG 
pkn2 ATTGTGGCTCGAGATGAAGT TTTGGTTTGGAAACATGCAA 
pax7 GAGGACCAAGCTGACAGAGG CTGGCAGAAGGTGGTTGAA 
myog GCTCAGCTCCCTCAACCA GCTGTGAGAGCTGCATTCG 
des CTGGAGCGCAGAATTGAATC GGCAGTGAGGTCTGGCTTAG 
ppara TTCGCAATCCATCGGCGAG CCACAGGATAAGTCACCGAGG 
ppard CAGGGCTGACTGCAAACGA CTGCCACAATGTCTCGATGTC 
pgc1a TCTGAGTCTGTATGGAGTGACAT CCAAGTCGTTCACATCTAGTTCA 
cpt1b CATGTATCGCCGTAAACTGGAC TGGTAGGAGCACATAGGCACT 
fabp3 TGGAGTTCGATGAGACAACAGC CTCTTGCCCGTCCCATTTCTG 
pdk4 GGAAGCATTGATCCTAACTGTGA GGTGAGAAGGAACATACACGATG 
srebp1c GTTGGCCCTACCCCTCC CTTCAGCGAGGCGGCTT 
fasn CCACAACTCCAAGGACACAG CTGCTCCACGAACTCAAACA 
scd1 CCTGCGGATCTTCCTTATCA GCCCATTCGTACACGTCATT 
acc2 CTGAGAGTGCGGAGGACTTC AGCGAGGATCTGAACTTCCA 
dgat1 GTCCCTCTGCGAATGTTCC GCTATTGGCTGTCCGATGAT 
gpat1 AACACCAGATGGACGGAAAG CCGAGCACAAGAGGTTTTTC 
Mouse Forward Reverse 
pkn2 CGACCAAAACTCCAAAGACA GTCTTCCCCAAGTGGCAATA 
36b4 CCCTGAAGTGCTCGACATCA TGCGGACACCCTCCAGAA 
 461 
462 
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Figure Legends 463 
Fig. 1. PKN2 knockdown decreases insulin responsiveness of glucose metabolism in 464 
skeletal muscle. (A) mRNA levels of PKN2, PAX7, MYOG (myogenin), and DES (desmin) 465 
and (B) protein abundance of PKN2, PAX7, and desmin in siRNA-treated primary HSMCs. 466 
(C) Representative brightfield images of siRNA-treated primary HSMC. Scale bar=100 µm. 467 
Basal and insulin-stimulated (120 nM) (D) glucose uptake, (E) incorporation into glycogen 468 
and (F) oxidation in siRNA-treated primary HSMC. Open bars: SCR, Closed Bars: siPKN2. 469 
*PKN2 effect, p<0.05. 
#
Insulin main effect, p<0.05. Results are mean ± SEM for n=5 470 
biological replicates. 471 
 472 
Fig. 2. PKN2 knockdown increases TBC1D4 phosphorylation in HSMCs. (A) Western 473 
blot analysis of PKN2, Akt, GSK3, and TBC1D4 protein and phosphorylation from basal and 474 
insulin-stimulated (120 nM; 15 min) primary HSMCs (representative immunoblot from n=5 475 
biological replicates). (B) Western blot analysis of PKN2 and Akt protein and 476 
phosphorylation in mouse quadriceps muscle 15 min following saline or insulin (5 IU/kg I.P.) 477 
injection (representative immunoblot from n=4 mice). (C) Quantification of P-TBC1D4
Ser318
 478 
abundance in basal and insulin-stimulated primary HSMCs. Open bars: SCR, Closed Bars: 479 
siPKN2. *PKN2 effect, p<0.05. 
#
Insulin main effect, p<0.05. Results are mean ± SEM for 480 
n=5 biological replicates. 481 
 482 
Fig. 3. PKN2 knockdown increases AMPK signaling. (A) Western blot analysis of P-483 
AMPK
Thr172
, AMPK, and P-ACC
Ser79
 in primary HSMCs incubated in the absence or 484 
presence of insulin (120 nM; 15 min) (representative immunoblot from n=5 biological 485 
replicates). Quantification of (B) P-AMPK
Thr172
 and (C) P-ACC
Ser79
 abundance. (D) Western 486 
blot analysis of P-ACC
Ser79 
abundance
 
in PKN2 siRNA-treated HEK293 cells overexpressing 487 
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caFYN (representative immunoblot from n=3 biological replicates). Open bars: SCR, Closed 488 
Bars: siPKN2. *PKN2 post-hoc effect. Results are mean ± SEM for n=5 biological replicates. 489 
  490 
Fig. 4. PKN2 knockdown increases fatty acid oxidation and incorporation into 491 
triglycerides. Palmitate (A) oxidation and (B) incorporation into lipid species in siRNA 492 
treated primary HSMC incubated in the absence or presence of AICAR (2 mM). mRNA level 493 
of (C) PGC-1α and (D) SREBP1c target genes in siRNA-treated primary HSMCs. Open bars: 494 
SCR, Closed Bars: siPKN2. *PKN2 post-hoc effect, p<0.05. 
#
AICAR main effect, p<0.05. 495 
Results are mean ± SEM for n=5 biological replicates. 496 
 497 
Fig. 5. PKN2 knockdown decreases mTOR signaling and protein synthesis. (A) Western 498 
blot analysis P-mTOR
Ser2448
, mTOR, P-S6
Ser235/236
, and S6 in primary HSMCs incubated in 499 
the absence or presence of insulin (120 nM; 15 min) (representative immunoblot from n=5 500 
biological replicates).  Quantification of (B) P-mTOR
Ser2448
 and (C) P-S6
Ser235/236
 abundance. 501 
(D) Protein synthesis in siRNA-treated primary HSMCs. *PKN2 effect, p<0.05. Open bars: 502 
SCR, Closed Bars: siPKN2. 
#
Insulin main effect, p<0.05. Results are mean ± SEM for n=5 503 
biological replicates. 504 
   505 
Fig. 6. PKN2 silencing in vivo decreases glucose uptake and activates AMPK. 506 
Contralateral tibialis anterior muscles were electroporated with shRNA targeting PKN2 or 507 
scrambled control. Seven days following electroportation 4 h fasted mice were administered 508 
an oral glucose load (3 g/kg) followed by I.P. injection of 
3
H-deoxyglucose. Tibialis anterior 509 
muscle was harvested 2 h following the oral glucose challenge and analyzed for: (A) PKN2, 510 
P-AMPK
Thr172
, AMPK, P-ACC
Ser79
 and ACC protein abundance (representative immunoblot 511 
from n=7 mice). (B) Quantification of PKN2 protein abundance, (C) in vivo glucose uptake 512 
 23 
(D) intramuscular glycogen content, (E) Quantification of P-AMPK
Thr172
 abundance and (F) 513 
P-ACC
Ser79
 abundance in PKN2 shRNA-treated mouse tibialis anterior muscle. *paired t-test, 514 
p<0.05. Results are mean ± SEM for n=7 mice.  515 
 516 
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